Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2014

View Archived Issues

Initial report on first-in-human study of 3-V Bioscience's TVB-2640

Valaciclovir approval expanded in Japan

FDA grants orphan drug status to vatiquinone for Rett syndrome

New murine models to study human hepatitis viral infection described at AASLD meeting

Transition Therapeutics reports results from ELND-005 study

Apellis to acquire Potentia Pharmaceuticals

Sanquin and Okklo collaborate to develop cyclodextrins for cardiovascular indications

Karus Therapeutics patents novel HDAC6 inhibitors

Nimbus Apollo reports new ACC2 inhibitors

SOM Biotech and Vall d'Hebron begin trial of repositioned drug for amyloidosis

New GABA(A) receptor agonists disclosed by Sichuan Haisco

MetrioPharm files IND application for immunomodulator MP-1032

A genetically attenuated P. falciparum as vaccine candidate

Cosentyx receives positive CHMP opinion for first-line treatment of psoriasis

Nintedanib obtains positive opinion in European Union for the treatment of IPF

Palovarotene receives EMA orphan medicinal product designation

In vivo protection with inactivated dengue virus antigens plus alphavirus adjuvant

EMA gives positive opinion for hepatitis C therapy Viekirax plus Exviera

Pharmacological profile of a novel PDE10A inhibitor, MT-3014

CHMP adopts positive opinion for Genzyme's Cerdelga

Studies compare time to ESRD in aHUS patients treated with supportive care or eculizumab

Kissei Pharmaceutical discloses new TRPM8 antagonists

Galapagos patents novel CFTR activators

European Commission approves Duaklir Genuair for COPD

CHMP backs Otezla for psoriasis and psoriatic arthritis

Signifor approved in E.U. to treat acromegaly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...